
Opinion|Videos|September 6, 2024
Key Factors to Consider when Switching to Biosimilars
Author(s)Sophia Humphreys, PharmD, MHA
Dr Humphreys discusses key factors to consider when switching to biosimilars.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- To what extent should the pharmacy team prioritize supporting the switch from a reference product to a biosimilar, and what factors should be considered in making this decision?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eli Lilly, Novo Nordisk Strike MFN Deals With Trump Administration to Lower GLP-1 Prices
2
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
3
Evolving Mortality Trends in Heart Failure and Vascular Disease: The Critical Role of Pharmacists in Addressing Cardiovascular Risk
4
Environmental Factors Could Influence Type 1 Diabetes Risk in Children Through Epigenetic Changes
5








































































































































































































